The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

NCT02660034 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

229

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

BIOLOGICAL: Tislelizumab
DRUG: Pamiparib

Sponsor

BeiGene

Collaborators

[object Object]